1. Scrip
  2. >>Business

Pipeline Catalysts Key Focus For Roche’s H1 Update

Swiss Pharma’s Increasing Diversification Also Big Theme

 
• By Sten Stovall

Despite legacy cancer drug sales still being hurt by biosimilars, Roche at the half-year mark is expected to give another good overall performance and underscore its growing product diversity and an increasing interest in rare diseases.  

Roche focus is growing therapeutic diversity, with multiple products and combinations • Source: Alamy

While Roche Holding AG remains synonymous with oncology, its early pipeline is now diversifying into other areas that offer fresh opportunity to discover truly innovative therapies, and it is this narrative that investors will be especially keen to explore when the Swiss drug maker reports its half-year update on 22 July.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.